CD22-CAR T Cells Induce Remissions in CD19-CAR Naïve and Resistant B-ALL

Chimeric antigen receptor (CAR) T-cells targeting CD19 mediate potent effects in relapsed/refractory pre-B cell acute lymphoblastic leukemia (B-ALL) but antigen loss is a frequent cause of resistance to CD19-targeted immunotherapy. CD22 is also expressed on most B-ALL and usually retained following...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Nat Med
Main Authors: Fry, Terry J., Shah, Nirali N., Orentas, Rimas J., Stetler-Stevenson, Maryalice, Yuan, Constance M., Ramakrishna, Sneha, Wolters, Pamela, Martin, Staci, Delbrook, Cindy, Yates, Bonnie, Shalabi, Haneen, Fountaine, Thomas J., Shern, Jack F., Majzner, Robbie G., Stroncek, David F., Sabatino, Marianna, Feng, Yang, Dimitrov, Dimiter S., Zhang, Ling, Nguyen, Sang, Qin, Haiying, Dropulic, Boro, Lee, Daniel W., Mackall, Crystal L.
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5774642/
https://ncbi.nlm.nih.gov/pubmed/29155426
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nm.4441
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados